Abhishek Jauhari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abhishek Jauhari has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Sanjay Yadav
Developmental Toxicology Laboratory, Systems Toxicology and Health Risk Assessment Group, CSIR- Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan, 31 Mahatma Gandhi Marg, Lucknow, Uttar Pradesh, 226001, India.
9 shared publications - Tanisha Singh
Developmental Toxicology Laboratory, Systems Toxicology and Health Risk Assessment Group, CSIR- Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan, 31 Mahatma Gandhi Marg, Lucknow, Uttar Pradesh, 226001, India
9 shared publications Devendra Parmar
Developmental Toxicology Laboratory, Systems Toxicology and Health Risk Assessment Group, CSIR- Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan, 31 Mahatma Gandhi Marg, Lucknow, Uttar Pradesh, 226001, India
6 shared publicationsParul Singh
Developmental Toxicology Laboratory, Systems Toxicology and Health Risk Assessment Group, CSIR- Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan, 31 Mahatma Gandhi Marg, Lucknow, Uttar Pradesh, 226001, India
5 shared publicationsAnkita Pandey
Developmental Toxicology Laboratory, Systems Toxicology and Health Risk Assessment Group, CSIR-Indian Institute of Toxicology Research (IITR), Vishvigyan Bhawan, 31 Mahatma Gandhi Marg, Lucknow, UP, 226001, India
4 shared publicationsTanisha Singh
University of Pittsburgh
4 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published byĀ Springer NatureĀ inĀ Research Square
METTL3-IGF2BP3 mā¶A axis drives mutant huntingtin stability and neurodegeneration in Huntingtonās disease
Huntingtonās disease (HD) is an inherited neurodegenerative disorder caused by CAG repeat expansion in the HTT gene, yet the molecular mechanisms linking mutant huntingtin (mHTT) to selective neuronal vulnerability remain incompletely understood. Emerging evidence suggests that post-transcriptional RNA regulation plays a role in HD pathogenesis; however, the contribution of epitranscriptomic modifications remains to be fully defined. Here, we identify Nā¶-methyladenosine (mā¶A) RNA methylation as a conserved and modifiable regulator of HD-associated neurodegeneration. Using complementary HD mouse models (R6/2 and zQ175), human postmortem striatum, and mHTT-expressing striatal cells, we demonstrate dysregulation of the mā¶A machinery, including upregulation of the writers METTL3/METTL14 and the reader IGF2BP3, accompanied by elevated global mā¶A levels in the cortex and striatum. Pharmacological inhibition or siRNA-mediated knockdown of METTL3 reduced global mā¶A, improved cell viability, suppressed caspase-3/9 activation, and attenuated inflammatory cytokine production in HD cells. Mechanistically, knockdown of either METTL3 or IGF2BP3 significantly reduced mHTT protein levels in sdhQ 111/111 striatal cells, identifying an mā¶A-IGF2BP3 axis that promotes mHTT accumulation and toxicity. Notably, these interventions had minimal effects in wild-type cells, indicating the selective vulnerability of mHTT-expressing cells. Together, these findings establish aberrant mā¶A RNA methylation as a driver of mHTT accumulation, neuronal apoptosis, and inflammation in HD, and highlight the METTL3-IGF2BP3 pathway as a promising epitranscriptomic therapeutic target.
- 8 July 2026
- Published byĀ Springer NatureĀ inĀ Research Square
Open AccessMETTL3-IGF2BP3 mā¶A axis drives mutant huntingtin stability and neurodegeneration in Huntingtonās disease
Huntingtonās disease (HD) is an inherited neurodegenerative disorder caused by CAG repeat expansion in the HTT gene, yet the molecular mechanisms linking mutant huntingtin (mHTT) to selective neuronal vulnerability remain incompletely understood. Emerging evidence suggests that post-transcriptional RNA regulation plays a role in HD pathogenesis; however, the contribution of epitranscriptomic modifications remains to be fully defined. Here, we identify Nā¶-methyladenosine (mā¶A) RNA methylation as a conserved and modifiable regulator of HD-associated neurodegeneration. Using complementary HD mouse models (R6/2 and zQ175), human postmortem striatum, and mHTT-expressing striatal cells, we demonstrate dysregulation of the mā¶A machinery, including upregulation of the writers METTL3/METTL14 and the reader IGF2BP3, accompanied by elevated global mā¶A levels in the cortex and striatum. Pharmacological inhibition or siRNA-mediated knockdown of METTL3 reduced global mā¶A, improved cell viability, suppressed caspase-3/9 activation, and attenuated inflammatory cytokine production in HD cells. Mechanistically, knockdown of either METTL3 or IGF2BP3 significantly reduced mHTT protein levels in sdhQ 111/111 striatal cells, identifying an mā¶A-IGF2BP3 axis that promotes mHTT accumulation and toxicity. Notably, these interventions had minimal effects in wild-type cells, indicating the selective vulnerability of mHTT-expressing cells. Together, these findings establish aberrant mā¶A RNA methylation as a driver of mHTT accumulation, neuronal apoptosis, and inflammation in HD, and highlight the METTL3-IGF2BP3 pathway as a promising epitranscriptomic therapeutic target.
- Open Access
- 15 May 2026
- Published byĀ ElsevierĀ inĀ Mitochondrion
- Vol.Ā 90, 102166
m6AāMediated epitranscriptomic control of mitochondrial dysfunction in neurodegeneration
- 15 May 2026
- Published byĀ ElsevierĀ inĀ Mitochondrion
- Vol.Ā 90, 102166
Open Accessm6AāMediated epitranscriptomic control of mitochondrial dysfunction in neurodegeneration
- 20 April 2026
- Published byĀ Springer NatureĀ inĀ Neurochemical Research
- Vol.Ā 51 Ā (3) , 142
MicroRNA and Proteomic Landscape of Brain Development
- 20 April 2026
- Published byĀ Springer NatureĀ inĀ Neurochemical Research
- Vol.Ā 51 Ā (3) , 142
MicroRNA and Proteomic Landscape of Brain Development
- Open Access
- 26 March 2026
- Published byĀ American Society for Clinical InvestigationĀ inĀ JCI Insight
- Vol.Ā 11 Ā (10)
Metabolic reprogramming is critical to microglial activation in Huntingtonās disease
Huntingtonās disease (HD) is a fatal neurodegenerative disease caused by an expanded polyglutamine (CAG) repeat in the N-terminal of the huntingtin protein ( HTT ). Microglial activation and elevated proinflammatory cytokines are observed in HD brains, but the mechanisms regulating neuroinflammation and microglial activation are poorly understood. Metformin-mediated neuroprotection has been demonstrated in experimental models of neurodegeneration, including HD. We found that metformin inhibits mitochondrial DNA (mtDNA) release and subsequent neuroinflammation in the cortex and striatum of a mouse model of HD. Moreover, elevated proinflammatory cytokines and microglial activation are inhibited by metformin in HD transgenic mouse brains. Metformin reduced pathological microglial clusters and shifted toward a quiescent, homeostatic phenotype. Metformin improved aberrant immunometabolism in HD mouse brains and primary microglia. Mechanistically, we found that metformin regulates mitochondrial fission, reprograms deregulated metabolism in HD microglia, and controls microglial activation and inflammation in HD transgenic mice.
- 26 March 2026
- Published byĀ American Society for Clinical InvestigationĀ inĀ JCI Insight
- Vol.Ā 11 Ā (10)
Open AccessMetabolic reprogramming is critical to microglial activation in Huntingtonās disease
Huntingtonās disease (HD) is a fatal neurodegenerative disease caused by an expanded polyglutamine (CAG) repeat in the N-terminal of the huntingtin protein ( HTT ). Microglial activation and elevated proinflammatory cytokines are observed in HD brains, but the mechanisms regulating neuroinflammation and microglial activation are poorly understood. Metformin-mediated neuroprotection has been demonstrated in experimental models of neurodegeneration, including HD. We found that metformin inhibits mitochondrial DNA (mtDNA) release and subsequent neuroinflammation in the cortex and striatum of a mouse model of HD. Moreover, elevated proinflammatory cytokines and microglial activation are inhibited by metformin in HD transgenic mouse brains. Metformin reduced pathological microglial clusters and shifted toward a quiescent, homeostatic phenotype. Metformin improved aberrant immunometabolism in HD mouse brains and primary microglia. Mechanistically, we found that metformin regulates mitochondrial fission, reprograms deregulated metabolism in HD microglia, and controls microglial activation and inflammation in HD transgenic mice.
- Top Cited PapersOpen Access
- 13 February 2026
- Published byĀ Springer NatureĀ inĀ Translational Neurodegeneration
- Vol.Ā 15 Ā (1) , 5
Mitochondrial DNA: a molecular switch driving sterile neuroinflammation
Mitochondrial DNA (mtDNA) plays a pivotal role in the regulation of neuroinflammation, acting as a potent trigger of innate immune responses when released into the cytoplasm or extracellular space. mtDNA is structurally similar to bacterial DNA, containing unmethylated CpG motifs that are readily recognized by immune sensors. Under conditions of cellular stress, injury, or mitochondrial dysfunction, mtDNA can escape into the cytoplasm, where it activates the cGAS (cyclic GMPāAMP synthase)āSTING (stimulator of interferon genes) signaling pathway, or it can be detected extracellularly by Toll-like receptors on immune cells. These signaling events lead to the production of pro-inflammatory cytokines and type I interferons, amplifying neuroinflammatory responses. In the central nervous system, this process contributes to the pathogenesis of various neurodegenerative and inflammatory conditions, such as Alzheimerās disease (AD), Parkinsonās disease (PD), Huntingtonās disease (HD), etc.. The dual role of mtDNA as both a damage-associated molecular pattern and a signaling molecule underscores its importance as a therapeutic target for modulating neuroinflammation and protecting against progressive neuronal damage. In this review, we will discuss the implications of mtDNA-mediated neuroinflammation in neurodegenerative diseases, including AD, PD, and HD, highlighting its potential as a diagnostic biomarker and therapeutic target.
- 13 February 2026
- Published byĀ Springer NatureĀ inĀ Translational Neurodegeneration
- Vol.Ā 15 Ā (1) , 5
Top Cited PapersOpen AccessMitochondrial DNA: a molecular switch driving sterile neuroinflammation
Mitochondrial DNA (mtDNA) plays a pivotal role in the regulation of neuroinflammation, acting as a potent trigger of innate immune responses when released into the cytoplasm or extracellular space. mtDNA is structurally similar to bacterial DNA, containing unmethylated CpG motifs that are readily recognized by immune sensors. Under conditions of cellular stress, injury, or mitochondrial dysfunction, mtDNA can escape into the cytoplasm, where it activates the cGAS (cyclic GMPāAMP synthase)āSTING (stimulator of interferon genes) signaling pathway, or it can be detected extracellularly by Toll-like receptors on immune cells. These signaling events lead to the production of pro-inflammatory cytokines and type I interferons, amplifying neuroinflammatory responses. In the central nervous system, this process contributes to the pathogenesis of various neurodegenerative and inflammatory conditions, such as Alzheimerās disease (AD), Parkinsonās disease (PD), Huntingtonās disease (HD), etc.. The dual role of mtDNA as both a damage-associated molecular pattern and a signaling molecule underscores its importance as a therapeutic target for modulating neuroinflammation and protecting against progressive neuronal damage. In this review, we will discuss the implications of mtDNA-mediated neuroinflammation in neurodegenerative diseases, including AD, PD, and HD, highlighting its potential as a diagnostic biomarker and therapeutic target.
- 19 January 2022
- Published byĀ ElsevierĀ inĀ Journal of Chemical Neuroanatomy
- Vol.Ā 120, 102072
Neurodevelopmental disorders and neurotoxicity: MicroRNA in focus
- 19 January 2022
- Published byĀ ElsevierĀ inĀ Journal of Chemical Neuroanatomy
- Vol.Ā 120, 102072
Neurodevelopmental disorders and neurotoxicity: MicroRNA in focus
- Open Access
- 1 June 2020
- Published byĀ American Society for Clinical InvestigationĀ inĀ Journal of Clinical Investigation
- Vol.Ā 130 Ā (6) , 3124-3136
Melatonin inhibits cytosolic mitochondrial DNAāinduced neuroinflammatory signaling in accelerated aging and neurodegeneration
Chronic inflammation is a pathologic feature of neurodegeneration and aging; however, the mechanism regulating this process is not understood. Melatonin, an endogenous free radical scavenger synthesized by neuronal mitochondria, decreases with aging and neurodegeneration. We proposed that insufficient melatonin levels impair mitochondrial homeostasis, resulting in mitochondrial DNA (mtDNA) release and activation of cytosolic DNA-mediated inflammatory response in neurons. We found increased mitochondrial oxidative stress and decreased mitochondrial membrane potential, with higher mtDNA release in brain and primary cerebro-cortical neurons of melatonin-deficient aralkylamine N-acetyltransferase (AANAT) knockout mice. Cytosolic mtDNA activated the cGAS/STING/IRF3 pathway, stimulating inflammatory cytokine generation. We found that Huntingtonās disease mice had increased mtDNA release, cGAS activation, and inflammation, all inhibited by exogenous melatonin. Thus, we demonstrated that cytosolic mtDNA activated the inflammatory response in aging and neurodegeneration, a process modulated by melatonin. Furthermore, our data suggest that AANAT knockout mice are a model of accelerated aging.
- 1 June 2020
- Published byĀ American Society for Clinical InvestigationĀ inĀ Journal of Clinical Investigation
- Vol.Ā 130 Ā (6) , 3124-3136
Open AccessMelatonin inhibits cytosolic mitochondrial DNAāinduced neuroinflammatory signaling in accelerated aging and neurodegeneration
Chronic inflammation is a pathologic feature of neurodegeneration and aging; however, the mechanism regulating this process is not understood. Melatonin, an endogenous free radical scavenger synthesized by neuronal mitochondria, decreases with aging and neurodegeneration. We proposed that insufficient melatonin levels impair mitochondrial homeostasis, resulting in mitochondrial DNA (mtDNA) release and activation of cytosolic DNA-mediated inflammatory response in neurons. We found increased mitochondrial oxidative stress and decreased mitochondrial membrane potential, with higher mtDNA release in brain and primary cerebro-cortical neurons of melatonin-deficient aralkylamine N-acetyltransferase (AANAT) knockout mice. Cytosolic mtDNA activated the cGAS/STING/IRF3 pathway, stimulating inflammatory cytokine generation. We found that Huntingtonās disease mice had increased mtDNA release, cGAS activation, and inflammation, all inhibited by exogenous melatonin. Thus, we demonstrated that cytosolic mtDNA activated the inflammatory response in aging and neurodegeneration, a process modulated by melatonin. Furthermore, our data suggest that AANAT knockout mice are a model of accelerated aging.
- Open Access
- 11 May 2020
- Published byĀ Oxford University Press (OUP)Ā inĀ Toxicological Sciences
- Vol.Ā 176 Ā (2) , 433-445
Coordinated Action of miR-146a and Parkin Gene Regulate Rotenone-induced Neurodegeneration
Mitochondrial dysfunction is a common cause in pathophysiology of different neurodegenerative diseases. Elimination of dysfunctional and damaged mitochondria is a key requirement for maintaining homeostasis and bioenergetics of degenerating neurons. Using global microRNA (miRNA) profiling in a systemic rotenone model of Parkinsonās disease, we have identified miR-146a as upmost-regulated miRNA, which is known as inflammation regulatory miRNA. Here, we report the role of activated nuclear factor kappa beta (NF-kβ) in miR-146a-mediated downregulation of Parkin protein, which inhibits clearance of damaged mitochondria and induces neurodegeneration. Our studies have shown that 4-week rotenone exposure (2.5 mg/kg b.wt) induced oxidative imbalance-mediated NF-kβ activation in 1-year-old ratās brain. Activated NF-kβ binds in promoter region of miR-146a gene and induces its transcription, which downregulates levels of Parkin protein. Decreased amount of Parkin protein results in accumulation of damaged and dysfunctional mitochondria, which further promotes the generation of reactive oxygen species in degenerating neurons. In conclusion, our studies have identified direct role of NF-kβ-mediated upregulation of miR-146a in regulating mitophagy through inhibition of the Parkin gene.
- 11 May 2020
- Published byĀ Oxford University Press (OUP)Ā inĀ Toxicological Sciences
- Vol.Ā 176 Ā (2) , 433-445
Open AccessCoordinated Action of miR-146a and Parkin Gene Regulate Rotenone-induced Neurodegeneration
Mitochondrial dysfunction is a common cause in pathophysiology of different neurodegenerative diseases. Elimination of dysfunctional and damaged mitochondria is a key requirement for maintaining homeostasis and bioenergetics of degenerating neurons. Using global microRNA (miRNA) profiling in a systemic rotenone model of Parkinsonās disease, we have identified miR-146a as upmost-regulated miRNA, which is known as inflammation regulatory miRNA. Here, we report the role of activated nuclear factor kappa beta (NF-kβ) in miR-146a-mediated downregulation of Parkin protein, which inhibits clearance of damaged mitochondria and induces neurodegeneration. Our studies have shown that 4-week rotenone exposure (2.5 mg/kg b.wt) induced oxidative imbalance-mediated NF-kβ activation in 1-year-old ratās brain. Activated NF-kβ binds in promoter region of miR-146a gene and induces its transcription, which downregulates levels of Parkin protein. Decreased amount of Parkin protein results in accumulation of damaged and dysfunctional mitochondria, which further promotes the generation of reactive oxygen species in degenerating neurons. In conclusion, our studies have identified direct role of NF-kβ-mediated upregulation of miR-146a in regulating mitophagy through inhibition of the Parkin gene.
- 8 April 2019
- Published byĀ Springer NatureĀ inĀ NeuroMolecular Medicine
- Vol.Ā 21 Ā (2) , 97-109
MiR-34 and MiR-200: Regulator of Cell Fate Plasticity and Neural Development
Studies from last two decades have established microRNAs (miRNAs) as the most influential regulator of gene expression, especially at the post-transcriptional stage. The family of small RNA molecules including miRNAs is highly conserved and expressed throughout the multicellular organism. MiRNAs regulate gene expression by binding to 3ā² UTR of protein-coding mRNAs and initiating either decay or movement of mRNAs to stress granules. Tissues or cells, which go through cell fate transformation like stem cells, brain cells, iPSCs, or cancer cells show very dynamic expression profile of miRNAs. Inability to pass the developmental stages of Dicer (miRNA maturation enzyme) knockout animals has confirmed that expression of mature and functional miRNAs is essential for proper development of different organs and tissues. Studies from our laboratory and elsewhere have demonstrated the role of miR-200 and miR-34 families in neural development and have shown higher expression of both families in mature and differentiated neurons. In present review, we have provided a general overview of miRNAs and focused on the role of miR-34 and miR-200, two miRNA families, which have the capability to change the phenotype and fate of a cell in different tissues and situations.
- 8 April 2019
- Published byĀ Springer NatureĀ inĀ NeuroMolecular Medicine
- Vol.Ā 21 Ā (2) , 97-109
MiR-34 and MiR-200: Regulator of Cell Fate Plasticity and Neural Development
Studies from last two decades have established microRNAs (miRNAs) as the most influential regulator of gene expression, especially at the post-transcriptional stage. The family of small RNA molecules including miRNAs is highly conserved and expressed throughout the multicellular organism. MiRNAs regulate gene expression by binding to 3ā² UTR of protein-coding mRNAs and initiating either decay or movement of mRNAs to stress granules. Tissues or cells, which go through cell fate transformation like stem cells, brain cells, iPSCs, or cancer cells show very dynamic expression profile of miRNAs. Inability to pass the developmental stages of Dicer (miRNA maturation enzyme) knockout animals has confirmed that expression of mature and functional miRNAs is essential for proper development of different organs and tissues. Studies from our laboratory and elsewhere have demonstrated the role of miR-200 and miR-34 families in neural development and have shown higher expression of both families in mature and differentiated neurons. In present review, we have provided a general overview of miRNAs and focused on the role of miR-34 and miR-200, two miRNA families, which have the capability to change the phenotype and fate of a cell in different tissues and situations.
- 4 April 2018
- Published byĀ Springer NatureĀ inĀ Molecular Neurobiology
- Vol.Ā 55 Ā (12) , 8978-8990
Expression of miR-145 and Its Target Proteins Are Regulated by miR-29b in Differentiated Neurons
MicroRNAs (miRNAs) are emerging as the most potential regulator of neuronal development. Recent studies from our lab and elsewhere have demonstrated a direct role of miRNAs in regulating neuronal differentiation and synaptogenesis. MicroRNA-145, a miRNA identified to regulate pluripotency of stem cells, downregulates the protein levels of reprogramming transcription factors (RTFs) like OCT4, SOX2, and KLF4 (cell, 137,647ā658,2009). Studies have shown that miR-145 is multifunctional and crucial for fate determination of neurons. In our recently published study, we have identified a set of miRNAs including miR-145 and miR-29b families differentially expressed in SH-SY5Y cells exposed sequentially with retinoic acid + brain-derived neurotrophic factor (RA+BDNF) for differentiation into mature neurons (Mol Neurobiol (2016) doi: https://doi.org/10.1007/s12035-016-0042-9 ). In the present study, we have identified the role of miR-29b in upregulation of miR-145, which is upregulated after exposure of RA+BDNF in a P53-dependent manner. In differentiating SH-SY5Y cells, expression of miR-29b downregulates expression of P85α, a P53 inhibitor, which results in upregulation of miR-145 and downregulation of RTF proteins. Ectopic expression of miR-145 and miR-29b in amounts equivalent to their endogenous expression has induced G1 phase cell cycle arrest. In conclusion, our studies have identified miR-29b as an upstream regulator of miR-145 and targets its RTF genes during differentiation of SH-SY5Y cells.
- 4 April 2018
- Published byĀ Springer NatureĀ inĀ Molecular Neurobiology
- Vol.Ā 55 Ā (12) , 8978-8990
Expression of miR-145 and Its Target Proteins Are Regulated by miR-29b in Differentiated Neurons
MicroRNAs (miRNAs) are emerging as the most potential regulator of neuronal development. Recent studies from our lab and elsewhere have demonstrated a direct role of miRNAs in regulating neuronal differentiation and synaptogenesis. MicroRNA-145, a miRNA identified to regulate pluripotency of stem cells, downregulates the protein levels of reprogramming transcription factors (RTFs) like OCT4, SOX2, and KLF4 (cell, 137,647ā658,2009). Studies have shown that miR-145 is multifunctional and crucial for fate determination of neurons. In our recently published study, we have identified a set of miRNAs including miR-145 and miR-29b families differentially expressed in SH-SY5Y cells exposed sequentially with retinoic acid + brain-derived neurotrophic factor (RA+BDNF) for differentiation into mature neurons (Mol Neurobiol (2016) doi: https://doi.org/10.1007/s12035-016-0042-9 ). In the present study, we have identified the role of miR-29b in upregulation of miR-145, which is upregulated after exposure of RA+BDNF in a P53-dependent manner. In differentiating SH-SY5Y cells, expression of miR-29b downregulates expression of P85α, a P53 inhibitor, which results in upregulation of miR-145 and downregulation of RTF proteins. Ectopic expression of miR-145 and miR-29b in amounts equivalent to their endogenous expression has induced G1 phase cell cycle arrest. In conclusion, our studies have identified miR-29b as an upstream regulator of miR-145 and targets its RTF genes during differentiation of SH-SY5Y cells.